NYSE · EVMN
Evommune, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for EVMN: Dec 10, 2026
Evommune, Inc. Common Stock is estimated to report earnings on 12/10/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.82. The reported EPS for the same quarter last year was $-8.07.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.82 | $-0.67 | $-1.01 | 6 |
| Dec 2026 | $-0.85 | $-0.66 | $-1.05 | 6 |
| Mar 2027 | $-0.97 | $-0.80 | $-1.15 | 3 |
| Jun 2027 | $-1.00 | $-0.78 | $-1.22 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · BNK Invest · Zacks · RTTNews- Fintel · Sep 15, 6:22 AM EDTEvommune Consensus Price Target Decreased by 13.25% to $24.48The average one-year price target for Evommune (NYSE:EVMN) has been revised to $24.48 / share. This is a decrease of 13.25% from the prior estimate of $28.22 dated August 25, 2026. These figures represent aggregate analyst targets compiled by Fintel, rather than a recommendation
- BNK Invest · Jul 13, 4:35 PM EDTEvommune Becomes Oversold (EVMN)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- BNK Invest · Jul 9, 11:49 AM EDTThursday 7/9 Insider Buying Report: LRMR, EVMNBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today
- Zacks · Jun 30, 11:15 AM EDTEVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary GoalEvommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.
- RTTNews · Jun 29, 9:43 AM EDTEvommune's Phase 2b Trial Of EVO756 Fails To Meet Primary Endpoint, Stock Falls(RTTNews) – Monday, Evommune, Inc. (EVMN) announced top-line results from its Phase 2b trial of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria.
- Fintel · Mar 18, 8:09 AM EDTClear Street Initiates Coverage of Evommune (EVMN) with Buy RecommendationFintel reports that on March 18, 2026, Clear Street initiated coverage of Evommune (NYSE:EVMN) with a Buy recommendation. Analyst Price Forecast Suggests 120.06% Upside
- The Motley Fool · Mar 10, 10:11 AM EDT1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next DecadeClinical-stage biotech Evommune is seen as a potential buyout candidate.
- RTTNews · Mar 5, 8:50 PM ESTEvommune, Inc Loss At -$28.27 Mln In Q4(RTTNews) – Evommune, Inc (EVMN) reported Loss for fourth quarter of -$28.27 million
- Fintel · Feb 25, 7:24 PM ESTEvommune (EVMN) Price Target Increased by 37.87% to 55.08The average one-year price target for Evommune (NYSE:EVMN) has been revised to $55.08 / share. This is an increase of 37.87% from the prior estimate of $39.95 dated February 1, 2026. The price target is an average of many targets provided by analysts. The late
- RTTNews · Feb 13, 10:39 AM ESTWeekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace(RTTNews) – The biotech sector witnessed a few regulatory setbacks, Type B meetings that went well, noteworthy approvals, acquisitions, and clinical trials that met primary endpoints across key therapeutic areas, including achondroplasia, asthma, skin cancers, and actinic keratos
- RTTNews · Feb 10, 10:45 AM ESTEvommune Stock Soars 51% Over Positive Top-Line Data From Atopic Dermatitis Study(RTTNews) – Shares of Evommune, Inc. (EVMN) are surging about 51 percent on Tuesday morning trading following the announcement of positive top-line data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis.
- RTTNews · Feb 10, 9:27 AM ESTEvommune Reports Strong Phase 2a Results As EVO301 Meets Primary Endpoint In Atopic Dermatitis(RTTNews) – Evommune, Inc. (EVMN) announced positive top-line data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis, highlighting that the study met its primary efficacy endpoint at Week 12 and demonstrated rapid, statisticall
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Evommune, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.